½ÃÀ庸°í¼­
»óǰÄÚµå
1819731

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå : ¹üÀ§, ºÎ¹®, µ¿Çâ, °æÀï ºÐ¼®(2021-2031³â)

Asia Pacific Anatomic Pathology Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 135 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÇØºÎ º´¸®ÇÐ ½ÃÀåÀº Å©°Ô ¼ºÀåÇÏ¿© 2023³â ¾à 72¾ï 5,284¸¸ ´Þ·¯, 2031³â¿¡´Â ÃßÁ¤ 140¾ï 3,208¸¸ ´Þ·¯¿¡ À̸£°í, 2023³âºÎÅÍ 2031³â±îÁö CAGRÀº 8.6%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

ÁÖ¿ä ¿ä¾à ¹× ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå °³¿ä

¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ÀÌ ÇØºÎ º´¸®ÇÐ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À̸ç, ÀÌ Áö¿ªÀÇ ´Ù¸¥ ±¹°¡µé¿¡ ´ëÇÑ ´õ ¸¹Àº ÅëÂû·ÂÀ» ¾ò°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, µðÁöÅÐ ¼Ö·ç¼Ç ¹× °í±Þ º´¸®ÇÐ µµ±¸ÀÇ Ã¤Åÿ¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. È£ÁÖ¿Í Çѱ¹°ú °°Àº ±¹°¡µéÀº Áö¼ÓÀûÀ¸·Î ÁøÈ­ÇÏ´Â °Ç°­ °ü¸® ½Ã½ºÅÛÀ» ÅëÇØ Å« ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­ ºÐ¼®

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀåÀº Á¦Ç° ¹× ¼­ºñ½º, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ¸¦ ±â¹ÝÀ¸·Î ¼¼ºÐÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

1. Á¦Ç° ¹× ¼­ºñ½º : ÀÌ ºÎ¹®¿¡´Â ¼­ºñ½º, Àåºñ, ¼Ò¸ðǰÀÌ Æ÷ÇԵ˴ϴÙ. 2023³â¿¡´Â ±â±¸°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¼­ºñ½º ºÐ¾ß´Â Á¶Á÷ º´¸®Çаú ¼¼Æ÷ º´¸®ÇÐÀ¸·Î ³ª´µ¸ç, Àåºñ ºÐ¾ß¿¡´Â ¸¶ÀÌÅ©·ÎÅè, Å©¶óÀÌ¿À½ºÅÈ, ÀÚµ¿ ¿°»ö±â, Á¶Á÷ ÇÁ·Î¼¼¼­ ¹× ±âŸ °ü·Ã µµ±¸°¡ Æ÷ÇԵ˴ϴÙ.

2. ¿ëµµ : ½ÃÀåÀº Áúº´ Áø´Ü, ¾à¹° ¹ß°ß ¹× °³¹ß µîÀ¸·Î ºÐ·ùµË´Ï´Ù. Áúº´ Áø´Ü ºÐ¾ß´Â 2023³â¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇßÁö¸¸, ÀÌ´Â ´Ù¾çÇÑ °Ç°­ »óÅÂÀÇ Æ¯Á¤¿¡ À־ ÇØºÎ º´¸®ÇÐÀÇ Áß¿äÇÑ ¿ªÇÒÀ» ¹Ý¿µÇÕ´Ï´Ù.

3. ÃÖÁ¾ »ç¿ëÀÚ : ÀÌ ºÎ¹®¿¡´Â º´¿ø, Á¶»ç ¿¬±¸¼Ò, Áø´Ü ½ÇÇè½Ç ¹× ±âŸ°¡ Æ÷ÇԵ˴ϴÙ. 2023³â ½ÃÀå Á¡À¯À²Àº º´¿øÀÌ °¡Àå Å©°í ÇØºÎ º´¸®ÇÐ ¼­ºñ½ºÀÇ À̿뿡 ÀÖ¾î Áß½ÉÀûÀÎ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå Àü¸Á

µðÁöÅÐ º´¸®ÇÐÀº µðÁöÅÐ ±â¼úÀ» Ȱ¿ëÇÏ¿© µ¥ÀÌÅÍ ¼öÁý ¹× °ü¸® ÇÁ·Î¼¼½º¸¦ °­È­ÇÏ´Â ÇØºÎ º´¸®ÇÐÀÇ ½ÅÈï ºÐ¾ßÀÔ´Ï´Ù. ÀÌ ±â¼ú Çõ½ÅÀº ½Ã·á Ãë±Þ°ú °ü·ÃµÈ À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí ÀÓ»ó½ÃÇè¿¡ ȯÀÚ µî·ÏÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ º´¸®ÇÐÀº ½Ã·á äÃë¿¡¼­ °á°ú±îÁö ¼Ò¿ä ½Ã°£À» ´ëÆø ´ÜÃàÇÒ ¼ö ÀÖÀ¸¹Ç·Î Áß¾Ó º´¸® ½É»ç °úÁ¤À» °£¼ÒÈ­Çϰí ÀÓ»ó½ÃÇèÀÇ È¿À²¼ºÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.

¸Ó½Å·¯´×(ML)°ú ÀΰøÁö´É(AI)À» µðÁöÅÐ º´¸®Çп¡ ÅëÇÕÇÏ¸é µ¥ÀÌÅÍ ºÐ¼®°ú °ü¸® ´É·ÂÀ» °­È­ÇÔÀ¸·Î½á ÀÌ ºÐ¾ß¿¡ º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ¸¹Àº ÇØºÎ º´¸®ÇÐ ½ÇÇè½ÇÀº µðÁöÅÐÈ­¿Í ÀΰøÁö´ÉÀÇ ÀÌÁ¡À» ÀνÄÇϰí ÀÖÀ¸¸ç Áø´Ü Á¤È®µµ, È¿À²¼º ¹× Àϰü¼º Çâ»óÀÌ ±â´ëµË´Ï´Ù. ÃÖ±Ù ±â¼úÀÇ Áøº¸¿Í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ½ÇÇè½Ç ¾÷¹«ÀÇ µðÁöÅÐÈ­¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

2023³â 11¿ù, ´Ù´Þ·Î½º ±×·ì°ú ¾ÆÀ̺¤½º ¸ÞµðÄà ¾Ö³Î¸®Æ½½º´Â ¾Ï Áø´ÜÀ» À§ÇÑ Á¾ÇÕÀûÀÎ ÀΰøÁö´É žÀç µðÁöÅÐ º´¸® ¼Ö·ç¼ÇÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¼Ö·ç¼ÇÀº Â÷¼¼´ë ÇØºÎ º´¸®ÇÐ Á¤º¸ ½Ã½ºÅÛ(AIS)°ú µðÁöÅÐ º´¸® ¼Ö·ç¼ÇÀ» ÅëÇØ ÇØºÎ º´¸®ÇÐ ½ÇÇè½ÇÀÇ ¿Ïº®ÇÑ µðÁöÅÐÈ­¸¦ ÃËÁøÇÏ°í µ¥ÀÌÅÍ¿Í AI¸¦ Ȱ¿ëÇÏ¿© »ç·Ê ¿ì¼±¼øÀ§, °í±Þ À̹ÌÁö ºÐ¼® ¹× ÀϰüµÈ Áø´ÜÀ» °³¼±ÇÕ´Ï´Ù. ÇØºÎ º´¸®ÇÐ °úÁ¤¿¡¼­ AI ÅëÇÕÀÇ Á߿伺ÀÌ ³ô¾ÆÁö¸é ¾ÕÀ¸·Î ¼ö³â°£ ½ÃÀå ¼ºÀåÀ» À̲ø¾î³»´Â Áß¿äÇÑ µ¿ÇâÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå ±¹°¡º° ÅëÂû·Â

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå¿¡´Â Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ µîÀÇ ±¹°¡°¡ Æ÷ÇԵ˴ϴÙ. 2023³â¿¡´Â Áß±¹ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ º¸°í¿¡ µû¸£¸é 2020³â »õ·Ó°Ô ¹ß»ýÇÏ´Â ¾Ï ȯÀÚ´Â 457¸¸¸í, ¾Ï °ü·Ã »ç¸ÁÀº 300¸¸¸íÀ¸·Î ÀÌ´Â ¼¼°è ÃÖ°íÀÔ´Ï´Ù. ÀÌ ¿ì·ÁÇØ¾ß ÇÒ µ¿Çâ¿¡ ÀÇÇØ Á¶±â ¾Ï °ËÁø, Áø´Ü, Ä¡·á¿¡ ´ëÇÑ ÁÖ¸ñÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

Áö³­ 20³â°£ Áß±¹ Á¤ºÎ´Â "³óÃÌ ¾Ï °ËÁø ÇÁ·Î±×·¥"À̳ª "³óÃÌÀÇ ¿©¼ºÀ» À§ÇÑ Àڱà °æºÎ¾Ï ¹× À¯¹æ¾Ï °ËÁø ÇÁ·Î±×·¥" µî, ¸î°³ÀÇ ´ë±Ô¸ð ¾Ï °ËÁøÀÇ ´ëó¸¦ ½Ç½ÃÇØ ¿Ô½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÁ·Î±×·¥¿¡ ÀÇÇØ ´Ù¾çÇÑ ¾ÏÀÇ Áý´Ü °ËÁøÀÇ ÁøÂûÀ²ÀÌ ´ëÆø Çâ»óÇØ, 1Â÷ ÀÇ·á½Ã¼³¿¡ À־ÀÇ ¾ÏÀÇ ¿¹¹æ°ú °ü¸®ÀÇ Çâ»ó¿¡ °øÇåÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ Áß±¹¿¡¼­´Â ±âÁ¸ÀÇ º´¸® Áø´Ü¹ý¿¡¼­ µðÁöÅÐ º´¸® Áø´Ü¹ýÀ¸·ÎÀÇ ÀüȯÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. »óÇÏÀÌ µðÁöÅÐ ÀÇ·á Çõ½Å ¼¾ÅÍÀÇ 2022³â º¸°í¼­¿¡ µû¸£¸é Á¶»ç ´ë»ó º´¿øÀÇ ¾à 40%°¡ µðÁöÅÐ º´¸® ½Ã½ºÅÛÀ» °³¹ß ÁßÀ̰ųª ÀÌ¹Ì ±¸ÃàµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ º´¿ø Áß »ó´ç¼ö´Â ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç Áø´Ü ´É·Â °­È­¿¡ ´ëÇÑ °­ÇÑ Çå½ÅÀ» º¸¿©ÁÝ´Ï´Ù. ¶ÇÇÑ 2022³â¿¡´Â ¿ø°Ý Áø·áÀÇ ¾à 23%°¡ µðÁöÅÐ º´¸® Áø´ÜÀ» ÀÌ¿ëÇϰí ÀÖ¾î °Ç°­ °ü¸®¿¡¼­ÀÇ µðÁöÅÐ º´¸® Áø´ÜÀÇ Á߿伺 Áõ°¡¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ÇØºÎ º´¸®ÇÐ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷

ÇØºÎ º´¸®ÇÐ ½ÃÀå¿¡¼­ À¯¸íÇÑ ±â¾÷À¸·Î´Â F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Hologic Inc, Agilent Technologies Inc, BioGenex Laboratories Inc, Diapath SpA, Bio SB, Merck KGaA, PHC Holdings Corporation µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº »ç¾÷ È®´ë, Á¦Ç° Çõ½Å, M&A µî ´Ù¾çÇÑ Àü·«À» Ãß±¸Çϰí Á¦Ç° ¶óÀξ÷À» Ãæ½ÇÈ÷ ÇÏ°í ½ÃÀå¿¡¼­ÀÇ Á¸Àç°¨À» ³ôÀ̰í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç
    • °¡¼³ÀÇ Ã¥Á¤
    • °Å½Ã°æÁ¦ ¿äÀκм®
    • ±âÃÊ ¼öÄ¡ÀÇ °³¹ß
    • µ¥ÀÌÅÍÀÇ »ï°¢Ãø·®
    • ±¹°¡ ·¹º§ µ¥ÀÌÅÍ

Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå »óȲ

  • PEST ºÐ¼®

Á¦5Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¾Ï°ú ½ÅÀ庴ÀÇ À¯º´·ü Áõ°¡
    • Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·
    • ¾ö°ÝÇÑ Á¤ºÎ ±ÔÁ¦
  • ½ÃÀå ±âȸ
    • °³º°È­ ÀǾàǰ¿¡ ´ëÇÑ ÁÖ¸ñÀÇ °íÁ¶
  • ÇâÈÄÀÇ µ¿Çâ
    • ÀΰøÁö´É°ú ¸Ó½Å·¯´×ÀÇ ÅëÇÕ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå ÇØºÎ º´¸®ÇÐ ½ÃÀå : ¾Æ½Ã¾ÆÅÂÆò¾ç ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå ¼öÀÍ, 2021³â-2031³â
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå ¿¹Ãø ºÐ¼®

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå ºÐ¼® - Á¦Ç° ¹× ¼­ºñ½ºº°

  • ¼­ºñ½ºº°
  • ±â±¸
  • ¼Ò¸ðǰ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå ºÐ¼® - ¿ëµµº°

  • Áúº´ Áø´Ü
  • ÀǾàǰ ¹ß°ß ¹× °³¹ß
  • ±âŸ

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå ºÐ¼® - ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
  • ¿¬±¸±â°ü
  • Áø´Ü ½ÇÇè½Ç
  • ±âŸ

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ÇØºÎ º´¸®ÇÐ ½ÃÀå : ±¹°¡º° ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±âŸ ±¹°¡

Á¦11Àå ¾÷°è Á¤¼¼

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇØºÎ º´¸®ÇÐ ½ÃÀå ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • F. Hoffmann-La Roche Ltd
  • Beckman Coulter Inc
  • Hologic Inc
  • Agilent Technologies Inc
  • BioGenex Laboratories Inc
  • Diapath SpA
  • Bio SB
  • Merck KGaA
  • PHC Holdings Corporation

Á¦13Àå ºÎ·Ï

SHW 25.10.01

The anatomic pathology market is projected to grow significantly, reaching an estimated US$ 14,032.08 million by 2031, up from US$ 7,252.84 million in 2023. This growth represents a compound annual growth rate (CAGR) of 8.6% from 2023 to 2031.

Executive Summary and Asia Pacific Anatomic Pathology Market Overview

In the Asia Pacific region, key players in the anatomic pathology market include China, Japan, India, Australia, and South Korea, with additional insights into other countries in the area. The growth of the anatomic pathology market in this region is primarily driven by the increasing prevalence of chronic diseases and the adoption of digital solutions and advanced pathology tools. Countries like Australia and South Korea are expected to present substantial growth opportunities due to their continuously evolving healthcare systems.

Market Segmentation Analysis

The Asia Pacific anatomic pathology market can be segmented based on products and services, applications, and end users.

1. Products and Services: This segment includes services, instruments, and consumables. In 2023, instruments accounted for the largest market share. The services segment is further divided into histopathology and cytopathology, while the instruments segment includes microtomes, cryostats, automatic stainers, tissue processors, and other related tools.

2. Applications: The market is categorized into disease diagnosis, drug discovery and development, among others. The disease diagnosis segment held the largest share in 2023, reflecting the critical role of anatomic pathology in identifying various health conditions.

3. End Users: This segment includes hospitals, research laboratories, diagnostic laboratories, and others. Hospitals represented the largest share of the market in 2023, highlighting their central role in utilizing anatomic pathology services.

Market Outlook for Asia Pacific Anatomic Pathology

Digital pathology is an emerging area within anatomic pathology that leverages digital technologies to enhance data collection and management processes. This innovation minimizes risks associated with specimen handling and has the potential to expedite patient enrollment in clinical trials. Furthermore, digital pathology can significantly reduce the turnaround time from sample collection to results, thereby streamlining the central pathology review process and improving trial efficiency.

The integration of machine learning (ML) and artificial intelligence (AI) into digital pathology is transforming the field by enhancing data analysis and management capabilities. Many anatomic pathology laboratories are increasingly recognizing the advantages of digitization and AI, which are expected to improve diagnostic accuracy, efficiency, and consistency. Recent technological advancements and regulatory approvals are further promoting the digitalization of laboratory operations.

In November 2023, Dedalus Group and Ibex Medical Analytics introduced a comprehensive AI-powered Digital Pathology Solution aimed at cancer diagnostics. This solution facilitates the complete digitization of anatomic pathology laboratories through a next-generation Anatomic Pathology Information System (AIS) and digital pathology solution, utilizing data and AI for improved case prioritization, advanced image analysis, and consistent diagnoses. The growing emphasis on AI integration in anatomic pathology processes is anticipated to be a significant trend that will drive market growth in the coming years.

Country Insights in the Asia Pacific Anatomic Pathology Market

The Asia Pacific anatomic pathology market includes countries such as China, Japan, India, Australia, South Korea, and others. In 2023, China held the largest market share. Cancer has become a major public health issue in China, with the World Health Organization (WHO) reporting 4.57 million new cancer cases and 3.00 million cancer-related deaths in 2020, the highest globally. This alarming trend has led to a heightened focus on early cancer screening, diagnosis, and treatment.

Over the past two decades, the Chinese government has implemented several large-scale cancer screening initiatives, such as the "Cancer Screening Program in Rural Areas" and the "Cervical Cancer and Breast Cancer Screening Program for Women in Rural Areas." These programs have significantly increased the rate of population-wide screenings for various cancers, contributing to better cancer prevention and control at primary healthcare facilities.

Moreover, China is transitioning from traditional pathological diagnosis methods to digital pathology. According to a 2022 report by the Shanghai Digital Medicine Innovation Center, approximately 40% of surveyed hospitals are either developing or have already established digital pathology systems. Many of these hospitals have invested substantial amounts in these systems, indicating a strong commitment to enhancing their diagnostic capabilities. The report also noted that around 23% of remote clinical consultations utilized digital pathology in 2022, reflecting its growing importance in the healthcare landscape.

Key Players in the Asia Pacific Anatomic Pathology Market

Prominent companies in the anatomic pathology market include F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Hologic Inc, Agilent Technologies Inc, BioGenex Laboratories Inc, Diapath S.p.A., Bio SB, Merck KGaA, and PHC Holdings Corporation, among others. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their offerings and increase their market presence.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Asia Pacific Anatomic Pathology Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Asia Pacific Anatomic Pathology Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increase in Prevalence of Cancer and Kidney Diseases
    • 5.1.2 Rise in Number of Strategic Initiatives
  • 5.2 Market Restraints
    • 5.2.1 Lack of Skilled Professionals
    • 5.2.2 Stringent Government Regulations
  • 5.3 Market Opportunities
    • 5.3.1 Growing Focus on Personalized Medicines
  • 5.4 Future Trends
    • 5.4.1 Integration of Artificial Intelligence and Machine Learning
  • 5.5 Impact of Drivers and Restraints:

6. Anatomic Pathology Market - Asia Pacific Analysis

  • 6.1 Asia Pacific Anatomic Pathology Market Revenue (US$ Million), 2021-2031
  • 6.2 Asia Pacific Anatomic Pathology Market Forecast Analysis

7. Asia Pacific Anatomic Pathology Market Analysis - by Product and Services

  • 7.1 Services
    • 7.1.1 Overview
    • 7.1.2 Services: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Instruments
    • 7.2.1 Overview
    • 7.2.2 Instruments: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Consumables
    • 7.3.1 Overview
    • 7.3.2 Consumables: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Anatomic Pathology Market Analysis - by Application

  • 8.1 Disease Diagnosis
    • 8.1.1 Overview
    • 8.1.2 Disease Diagnosis: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Drug Discovery and Development
    • 8.2.1 Overview
    • 8.2.2 Drug Discovery and Development: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Anatomic Pathology Market Analysis - by End User

  • 9.1 Hospitals
    • 9.1.1 Overview
    • 9.1.2 Hospitals: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Research Laboratories
    • 9.2.1 Overview
    • 9.2.2 Research Laboratories: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Diagnostic Laboratories
    • 9.3.1 Overview
    • 9.3.2 Diagnostic Laboratories: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Anatomic Pathology Market - Country Analysis

  • 10.1 Asia Pacific
    • 10.1.1 Asia Pacific Anatomic Pathology Market Overview
    • 10.1.2 Asia Pacific Anatomic Pathology Market - Revenue and Forecast Analysis - by Country
      • 10.1.2.1 China: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.2.1.1 China: Asia Pacific Anatomic Pathology Market Breakdown, by Product and Services
          • 10.1.2.1.1.1 China: Asia Pacific Anatomic Pathology Market Breakdown, by Services
          • 10.1.2.1.1.2 China: Asia Pacific Anatomic Pathology Market Breakdown, by Instruments
        • 10.1.2.1.2 China: Asia Pacific Anatomic Pathology Market Breakdown, by Application
        • 10.1.2.1.3 China: Asia Pacific Anatomic Pathology Market Breakdown, by End User
      • 10.1.2.2 Japan: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.2.2.1 Japan: Asia Pacific Anatomic Pathology Market Breakdown, by Product and Services
          • 10.1.2.2.1.1 Japan: Asia Pacific Anatomic Pathology Market Breakdown, by Services
          • 10.1.2.2.1.2 Japan: Asia Pacific Anatomic Pathology Market Breakdown, by Instruments
        • 10.1.2.2.2 Japan: Asia Pacific Anatomic Pathology Market Breakdown, by Application
        • 10.1.2.2.3 Japan: Asia Pacific Anatomic Pathology Market Breakdown, by End User
      • 10.1.2.3 India: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.2.3.1 India: Asia Pacific Anatomic Pathology Market Breakdown, by Product and Services
          • 10.1.2.3.1.1 India: Asia Pacific Anatomic Pathology Market Breakdown, by Services
          • 10.1.2.3.1.2 India: Asia Pacific Anatomic Pathology Market Breakdown, by Instruments
        • 10.1.2.3.2 India: Asia Pacific Anatomic Pathology Market Breakdown, by Application
        • 10.1.2.3.3 India: Asia Pacific Anatomic Pathology Market Breakdown, by End User
      • 10.1.2.4 Australia: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.2.4.1 Australia: Asia Pacific Anatomic Pathology Market Breakdown, by Product and Services
          • 10.1.2.4.1.1 Australia: Asia Pacific Anatomic Pathology Market Breakdown, by Services
          • 10.1.2.4.1.2 Australia: Asia Pacific Anatomic Pathology Market Breakdown, by Instruments
        • 10.1.2.4.2 Australia: Asia Pacific Anatomic Pathology Market Breakdown, by Application
        • 10.1.2.4.3 Australia: Asia Pacific Anatomic Pathology Market Breakdown, by End User
      • 10.1.2.5 South Korea: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.2.5.1 South Korea: Asia Pacific Anatomic Pathology Market Breakdown, by Product and Services
          • 10.1.2.5.1.1 South Korea: Asia Pacific Anatomic Pathology Market Breakdown, by Services
          • 10.1.2.5.1.2 South Korea: Asia Pacific Anatomic Pathology Market Breakdown, by Instruments
        • 10.1.2.5.2 South Korea: Asia Pacific Anatomic Pathology Market Breakdown, by Application
        • 10.1.2.5.3 South Korea: Asia Pacific Anatomic Pathology Market Breakdown, by End User
      • 10.1.2.6 Rest of APAC: Asia Pacific Anatomic Pathology Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.2.6.1 Rest of APAC: Asia Pacific Anatomic Pathology Market Breakdown, by Product and Services
          • 10.1.2.6.1.1 Rest of APAC: Asia Pacific Anatomic Pathology Market Breakdown, by Services
          • 10.1.2.6.1.2 Rest of APAC: Asia Pacific Anatomic Pathology Market Breakdown, by Instruments
        • 10.1.2.6.2 Rest of APAC: Asia Pacific Anatomic Pathology Market Breakdown, by Application
        • 10.1.2.6.3 Rest of APAC: Asia Pacific Anatomic Pathology Market Breakdown, by End User

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Asia Pacific Anatomic Pathology Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 F. Hoffmann-La Roche Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Beckman Coulter Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Hologic Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Agilent Technologies Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 BioGenex Laboratories Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Diapath S.p.A.
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Bio SB
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Merck KGaA
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 PHC Holdings Corporation
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦